Alloy Therapeutics combines proprietary AI/ML, real-world data, and wet-lab execution to provide integrated discovery and development services across multiple biologic modalities, including antibodies, bispecifics, genetic medicines, TCRms, cell therapies, and drug delivery. Since its 2017 founding, Alloy has partnered with over 200 organizations, generated more than 100 licensed therapeutic programs, and advanced 22 programs into clinical development, with two programs in Phase 3. The company has expanded beyond discovery into pharmacology, preclinical and clinical development services, and biologics manufacturing, positioning itself as a full-stack biotech infrastructure provider. Alloy operates a distributed model with centers of excellence across the U.S., Japan, the Middle East, and other emerging markets. Financially, the company just raised $40 million in a Series E at a $1.0 billion valuation to scale its services and accelerate its AI/ML and data capabilities.

Total raised

$157M

Funding rounds

3

Latest round

Series E

Latest activity

Apr 2026